Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Masaki Ri

Showing results (81-90 of 116) with videos related to

Pageof 12
Sort By:
Haematologica|August 5, 2018
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphomaShiori Kinoshita, Takashi Ishida, Asahi Ito, et al.
Cancer Science|September 6, 2008
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myelomaHiroki Yano, Satoshi Kayukawa, Shinsuke Iida, et al.
Cancer Science|September 2, 2022
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohortMasaki Ri, Kenshi Suzuki, Tadao Ishida, et al.
Scientific Reports|May 11, 2019
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma CellsHiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, et al.
International Journal of Hematology|September 6, 2015
Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cellsShohei Mizuno, Ichiro Hanamura, Akinobu Ota, et al.
Cancer Science|October 29, 2017
Clinical significance of tryptophan catabolism in Hodgkin lymphomaAyako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
Cancer Science|October 9, 2021
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Dai Maruyama, et al.
Internal Medicine (Tokyo, Japan)|January 4, 2026
An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma ProgressionYoko Nakanishi, Masaki Ri, Shiori Mizutani, et al.
Cancer Science|June 28, 2012
Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphomaSusumu Suzuki, Ayako Masaki, Takashi Ishida, et al.
International Journal of Hematology|May 23, 2019
Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myelomaReham Ashour, Masaki Ri, Sanaa Shaker Aly, et al.
Pageof 12

Showing results (81-90 of 116) with videos related to

Sort By:
Pageof 12
Haematologica|August 5, 2018
Cyclin-dependent kinase 9 as a potential specific molecular target in NK-cell leukemia/lymphomaShiori Kinoshita, Takashi Ishida, Asahi Ito, et al.
Cancer Science|September 6, 2008
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myelomaHiroki Yano, Satoshi Kayukawa, Shinsuke Iida, et al.
Cancer Science|September 2, 2022
Ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma: CARTITUDE-1 (phase 2) Japanese cohortMasaki Ri, Kenshi Suzuki, Tadao Ishida, et al.
Scientific Reports|May 11, 2019
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma CellsHiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, et al.
International Journal of Hematology|September 6, 2015
Overexpression of salivary-type amylase reduces the sensitivity to bortezomib in multiple myeloma cellsShohei Mizuno, Ichiro Hanamura, Akinobu Ota, et al.
Cancer Science|October 29, 2017
Clinical significance of tryptophan catabolism in Hodgkin lymphomaAyako Masaki, Takashi Ishida, Yasuhiro Maeda, et al.
Cancer Science|October 9, 2021
HLA genotyping in Japanese patients with multiple myeloma receiving bortezomib: An exploratory biomarker study of JCOG1105 (JCOG1105A1)Masaki Ri, Shinsuke Iida, Dai Maruyama, et al.
Internal Medicine (Tokyo, Japan)|January 4, 2026
An Analysis of Four Patients Discontinuing Idecabtagene Vicleucel after Leukapheresis due to Multiple Myeloma ProgressionYoko Nakanishi, Masaki Ri, Shiori Mizutani, et al.
Cancer Science|June 28, 2012
Tax is a potential molecular target for immunotherapy of adult T-cell leukemia/lymphomaSusumu Suzuki, Ayako Masaki, Takashi Ishida, et al.
International Journal of Hematology|May 23, 2019
Expression analysis of two SLAM family receptors, SLAMF2 and SLAMF7, in patients with multiple myelomaReham Ashour, Masaki Ri, Sanaa Shaker Aly, et al.
Pageof 12